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increasingly used for dosimetric verification. We have 
investigated the use of the TheraView CCD camera-based 
EPID for transmit dosimetry and developed a calibration 
method using the PTW OCTAVIUS 2D array of ion chambers. 
Materials and Methods: In order to use TheraView EPID for 
dosimetric purposes, several preliminary tests have been 
done, including the need for extra build-up thickness, 
stability, short and long-terms reproducibility, dose history, 
linearity, and output factor measurements. In order to 
predict patient-transmitted dose map, acquired electronic 
portal image (EPI) pixel values were converted to dose by a 
fourth order polynomial regression model. To correct EPIs, 
the off-axis ratio of dose profiles measured by EPID and 2D 
array detector were used to derive correction factor matrices 
(CFMs). Crosstalk effect and non-uniformity of EPI due to the 
45º tilted mirror have been reported in other studies, 
corrected by the CFM. To speed up this process, an in-house 
program called SBUDose was developed. The program 
automatically performs these tasks and generates a report. 
Results: The corrected relative dose maps acquired for 
different conditions, measured using the EPID were compared 
with the 2D array detector images using a gamma function 
algorithm. In each case, more than 90% of points fell within 
3% of the maximum dose and 3 mm distance to agreement. 
Conclusions: We have found that TheraView fluoroscopic 
EPID can be accurately calibrated for in-vivo dosimetry.  
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Purpose/Objective: The study was aimed to check treatment 
accuracy and definition of action levels during clinical 
implementation of in vivo dosimetry as a part of quality 
assurance program. Treatment accuracy was quantified as 
the ratio of the measured dose at accelerator and the 
expected dose from the treatment planning system (TPS). 
Materials and Methods: Calibration and corrections factors 
for in vivo entrance dose measurements for semiconductor 
diodes were determined as recommended by ESTRO Booklet 
No.5. The patients were divided in categories according to 
tumor localization, patient immobilization and irradiation 
technique used, in order to investigate and detect the groups 
for which the uncertainty was larger or for which a 
systematic error occurred. The tolerance level assessments 
for different patient groups were determined. Initial 
tolerance level of 5% was applied for all fields. 
Results: In this study, entrance dose measurements were 
performed for total 451 treatment fields, of 338 patients 
over one year period. The mean value and the standard 
deviation for different groups were: Breast: 
+1.0%±2.89%(1SD), Brain and head and neck: 
+0.74%±2.04%(1SD), Isocentric pelvis and abdomen: 
+0.1%±2.86%(1SD), All measurements: +0.72%±2.64%(1SD). 
Deviations larger than 5% were detected in 19 cases (4.3%) of 
all measurements and most of them, 16 cases (84%), were 
detected for breast treatment site. The tolerance level for 
brain and head and neck site was changed to 4%, for breast 
site was changed to 6% and for isocentric pelvis and abdomen 
site tolerance level was kept at initial level of 5%.  
Conclusions: In our experience, systematic in vivo dosimetry 
proved to be a very useful tool for quality assurance of a 
patient plan and treatment, both in detecting systematic 
errors and for estimating the accuracy of treatment delivery. 
Correct assessment of tolerance levels should minimize the 
number of repeats required and give the full confidence that 
patients are being treated as planned.  
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Purpose/Objective: The validation of a novel digital thermal 
neutron detector TNRD has been carried out for clinical 
applications. The results obtained by our group, indicated 
that the estimation of neutron doses, both in phantom and 
patients are perfectly feasible with this detector [1]. 
Although differences among the two diodes that compose the 
detectors in terms of photon sensitivity were reduced in the 
manufacturing process, experiments have shown them not to 
be completely reliable in some special clinical environment. 
The goal would be to find a relation between dose-signal 
responses with photon dose and energy, in order to establish 
TNRD limitations in clinical environments.  
Materials and Methods: The 60Co photon source used is a 
Gammabeam® X200 irradiator, that provides gamma photons 
(with energies of 1.17 and 1.33 MeV) in a wide range of dose 
rate (0.05-400 Gy/h), obtained with different attenuation 
systems. The linac used is a Primus Siemens with 6 MV and a 
40x10 cm2 field. Measurements were performed with a PTW 
Farmer ionization chamber and Thermal Neutron Rate 
Detector (TNRD), based on a pair of photodiodes and 
sensitized to thermal neutrons [2]. Pure photon response of 
TNRD was studied in the 60Co facility for dose rates ranging 
from 0 to 4 cGy/min. As we have already confirmed that 
neutron presence in 6 MV is negligible, measurements ranging 
from 0.1 to 4.6 cGy photon doses were performed for 
different out-of-field detector positions.  
Results: Although we expected to obtain a constant signal-
dose relation for TNRD, different behavior was observed at 
both facilities. A higher reading is obtained always for the 
60Co measurements, being almost 7 times bigger for low doses 
(0.12 cGy) and around 3 times at higher ones (4.3 cGy). TNRD 
energy response, can be estimated based on the mass-energy 
attenuation coefficient (µen/ρ) of 14Si (main component of 
